Serum-Free Media vs. FBS

The cell culture media landscape is evolving rapidly. Companies like Sartorius (through their Biological Industries acquisition), Thermo Fisher, and Corning are investing heavily in serum-free and chemically defined media formulations. Their marketing message is clear: serum-free is the future, and FBS is a relic of the past.

The Reality: Despite industry push toward serum-free, over 70% of cell culture labs still rely on FBS. The transition requires extensive optimization for each cell line — there's no universal serum-free replacement. Choose based on your specific needs, not trends.

The reality is nuanced. Serum-free media is genuinely superior for specific applications — particularly GMP manufacturing of cell and gene therapies. But for the vast majority of basic research, protocol development, and routine cell culture, FBS remains the gold standard for good reasons.

Our position: We sell FBS. We're transparent about that. But we're also scientists who understand cell biology. This guide will tell you honestly when serum-free works and when FBS is still your best option — because earning your trust matters more than a single sale.

If your application genuinely benefits from serum-free media, follow this protocol:

• Maintain parallel cultures (FBS and serum-free) for minimum 5 passages
• Gradual adaptation — reduce FBS 2% per passage (10% → 8% → 6% → 4% → 2% → 0%)
• Document growth curves — doubling time, viability, morphology at each step
• Validate functional assays — your key readouts must remain consistent
• Budget for failures — plan for 2–4 optimization rounds per cell line
• Keep FBS backup stock — if your serum-free culture crashes, you need a recovery option